Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma
Source: PMLiVE
You may also like
SMC recommends VEOZA for moderate to severe menopausal...
SMC backs Columvi combination for second-line lymphoma...
New Lung Model Reveals RSV Immune Response, Points to...
Mung Bean Pan-Genome Study Maps Key Genes for Yield...
Immune Evasion Uncovered by Virome-Wide Ubiquitin...
Genetic Map Opens Door to Development of New Therapies...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.